Significant Agreements - Novo Nordisk Share Purchase Agreement (Details) - USD ($)		1 Months Ended	12 Months Ended
	Jul. 08, 2021	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Accounts receivable		$ 0	$ 5,159,000	$ 0
Accounts Receivable, after Allowance for Credit Loss			0
Novo Nordisk
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Share Purchase Agreement, Upfront Payment	$ 60,000,000
Share Purchase Agreement, Potential Payment Upon Achievement of Development and Sales Milestones			1,130,000,000
Revenue from License and Intellectual Property, Share Purchase Agreement			$ 0	(40,000,000)	$ (60,700,000)
Milestone achievement, clinical milestone		40,000,000
Accounts Receivable, after Allowance for Credit Loss		$ 0		$ 0
Novo Nordisk | Transition services
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue from License and Intellectual Property, Share Purchase Agreement	$ 700,000